| 15.88 1.02 (6.86%) | 10-24 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.9 | 1-year : | 24.41 |
| Resists | First : | 17.89 | Second : | 20.9 |
| Pivot price | 15.62  |
|||
| Supports | First : | 12.31 | Second : | 8.85 |
| MAs | MA(5) : | 15.63  |
MA(20) : | 14.43 |
| MA(100) : | 10.54 |
MA(250) : | 7.19 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 54.6 |
D(3) : | 63.1 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 17.89 | Low : | 0.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DBVT ] has closed below upper band by 42.2%. Bollinger Bands are 27.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.6 - 15.75 | 15.75 - 15.84 |
| Low: | 14.49 - 14.68 | 14.68 - 14.8 |
| Close: | 14.64 - 14.95 | 14.95 - 15.14 |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Sat, 18 Oct 2025
Why DBV Technologies S.A. (DBV) stock remains top rated - Earnings Trend Report & Safe Entry Trade Signal Reports - nchmf.gov.vn
Fri, 17 Oct 2025
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Mon, 06 Oct 2025
$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan
Thu, 02 Oct 2025
Can DBV's Modified Viaskin Patch Overcome Past Setbacks In Q4 2025? - RTTNews
Thu, 18 Sep 2025
Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan
Thu, 18 Sep 2025
DBV Technologies Announces Resignation of Board Member - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 7.942e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 806.1 % |
| Return on Equity (ttm) | -59.2 % |
| Qtrly Rev. Growth | 3.8e+006 % |
| Gross Profit (p.s.) | 60.93 |
| Sales Per Share | -344.4 |
| EBITDA (p.s.) | 8.83721e+006 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 10.86 |
| Dividend | 0 |
| Forward Dividend | 18700 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|